Key Takeaways
- “Gynaecologic cancer” is not one diagnosis. Cervical, endometrial, ovarian/fallopian/peritoneal, vulvar, vaginal and gestational trophoblastic cancers have different staging systems, operations, biomarkers and treatment sequences.[1][2][3][4]
- Ask for a pathology diagnosis that names the organ, histological type, grade and required ancillary tests. A translated label such as “uterine cancer” is not enough to plan treatment.
- The multidisciplinary meeting should answer a case-specific decision—such as primary cytoreductive surgery versus chemotherapy first—not merely record that several departments attended.
- Imaging must match the cancer and decision. Original DICOM studies, operative notes and pathology material are needed for an independent Chinese review; tumour markers alone do not establish stage or operability.
- Fertility and ovarian-function discussions belong before hysterectomy, pelvic radiation or gonadotoxic systemic therapy. Selected early cancers may have fertility-sparing pathways, but eligibility is narrow and oncologic safety comes first.[5][6]
- Molecular and germline results can affect treatment and relatives. Endometrial cancer increasingly uses POLE, mismatch-repair, p53 and NSMP classification; ovarian cancer planning may require homologous-recombination and hereditary-risk assessment.[2][7]
Content
The phrase “multidisciplinary care” is useful only when it changes a decision and assigns responsibility. A conference that produces no diagnosis, no stage, no treatment order and no contingency is not a plan. For an international patient, the output must also survive travel: another team should be able to see what was decided, why and who handles the next problem.
China's National Health Commission has issued separate national guidance for cervical, endometrial and ovarian cancers rather than treating them as one disease family.[8] That is the right organising principle for this article: establish the exact primary cancer first, then bring in the disciplines required by that cancer and its stage.
Stabilise urgent problems before arranging international care
Heavy vaginal bleeding with faintness, severe anaemia, fever with neutropenia, uncontrolled vomiting, new leg swelling or breathlessness, bowel obstruction symptoms, inability to urinate, severe pain or rapidly worsening weakness requires prompt local assessment. A pelvic mass can also twist, rupture, obstruct a ureter or bleed before a final cancer diagnosis exists.
Do not delay emergency transfusion, antibiotics, drainage, anticoagulation assessment or decompression while waiting for translation or a remote opinion. Once stable, include the emergency event and treatment in the cancer timeline because it may change performance status, operative risk and sequencing.
Replace the umbrella label with a complete diagnostic sentence
Start the case summary with a line such as: “High-grade serous carcinoma, likely tubo-ovarian primary, with peritoneal disease on CT; tissue review and resectability assessment pending.” It is more useful than “advanced ovarian cancer.”
The pathology packet should contain:
- specimen site and method—biopsy, cone, curettage, hysteroscopy, oophorectomy or cytoreductive surgery;
- histological type and grade;
- depth of invasion, lymphovascular invasion, margins and lymph nodes when applicable;
- immunohistochemistry and molecular results;
- cytology and tumour-marker context where relevant;
- original report, addenda and translated report; and
- access to H&E slides, unstained slides, block or validated whole-slide images for review.
Site matters. A high-grade serous carcinoma involving ovary and peritoneum may originate in the fallopian tube; an adenocarcinoma involving cervix and endometrium needs a primary-site decision; a uterine sarcoma follows a different pathway from endometrial carcinoma. Ask the reviewing pathologist to state what is established, what remains uncertain and which test could resolve it.
Stage the right cancer with the right evidence
Do not copy a stage from a referral email without its basis. Record whether the stage is clinical, surgical/pathological or provisional and which FIGO or TNM version is used.
Cervical cancer staging relies on pelvic examination, pathology and imaging as appropriate; treatment may involve surgery for selected early disease or chemoradiation with brachytherapy for many locally advanced cases.[3]
Endometrial cancer risk depends on histology, grade, myometrial and cervical invasion, lymphovascular invasion, nodes and molecular class. NCI notes that POLE-mutated, mismatch-repair-deficient, NSMP and p53-abnormal classification is encouraged when feasible because it can affect prognosis and adjuvant or systemic decisions.[2]
Ovarian, fallopian-tube and primary peritoneal epithelial cancers often spread across the peritoneal cavity. The key pre-treatment question may be whether complete or near-complete cytoreduction appears achievable with acceptable risk, or whether biopsy and chemotherapy should precede interval surgery.[1]
Vulvar and vaginal cancers require precise lesion, nodal and functional mapping. For vulvar cancer, modern surgery has moved toward more limited resection in selected patients to reduce morbidity, sometimes combined with radiation.[4]
A cross-border imaging set may include pelvic MRI, contrast CT of chest/abdomen/pelvis, PET/CT for a defined question, ultrasound and prior studies. Send original DICOM series and reports. Ask the Chinese team to list which study it accepts, which must be repeated and whether the reason is image quality, staging completeness, contrast phase, elapsed time or treatment planning—not simply “hospital policy.”
Make the tumour board produce a decision record
The necessary participants vary, but a gynaecologic-oncology core often includes specialist surgery, pathology, radiology, radiation oncology and medical oncology. Add interventional radiology, genetics, reproductive endocrinology, urology, colorectal surgery, anaesthesia, nutrition, palliative care, rehabilitation and psycho-oncology when the case requires them.
Ask the meeting to document:
- confirmed working diagnosis and unresolved differential;
- stage and evidence used;
- treatment intent—curative, life-prolonging, symptom-directed or diagnostic;
- first treatment and its objective;
- alternatives, including observation or local treatment where reasonable;
- patient-specific benefits and major harms;
- missing tests that could change the choice;
- conditions that would switch the pathway; and
- named clinician responsible for the next step and for complications.
If the recommendation is conditional—“operate if review shows resectable disease; otherwise biopsy then chemotherapy”—retain both branches. A coordinator's summary saying “MDT recommends comprehensive treatment” has almost no clinical value.
Compare surgery by oncologic objective, not access route
The surgical question differs by primary cancer. It may be cone biopsy or radical trachelectomy for selected cervical cancer, hysterectomy with nodal assessment for endometrial cancer, cytoreduction for ovarian cancer, or tailored local and nodal surgery for vulvar disease.[1][2][3][4]
The proposal should state:
- operation, organs expected to be removed and structures at risk;
- open, laparoscopic or robotic access and why it suits this cancer;
- lymph-node plan, including whether sentinel-node mapping is used and what happens if mapping fails;
- criteria for bowel, urinary, diaphragmatic or upper-abdominal procedures;
- desired oncologic endpoint, such as negative margins or no visible residual disease;
- conditions for stopping, staging only or changing to another treatment sequence;
- need for ICU, blood products and specialist backup; and
- specimen orientation and pathology communication.
“Minimally invasive” is not itself an oncologic outcome. The centre should explain whether the proposed route is supported for this diagnosis and stage and whether specimen extraction risks fragmentation. Prior surgery, radiation, obesity, frailty, thrombosis risk and disease distribution can change the route.
For suspected advanced tubo-ovarian cancer, ask who judged resectability, whether diagnostic laparoscopy is proposed, which upper-abdominal procedures the team can perform, and how residual disease will be recorded. NCI describes surgery plus platinum-based chemotherapy as a central treatment framework, with surgery before or after chemotherapy depending on the situation.[1]
Radiation planning must include brachytherapy when it is part of the standard pathway
Pelvic external-beam radiotherapy and brachytherapy are different treatments. For many cervical-cancer pathways, the plan is incomplete if it discusses external radiation and chemotherapy but does not state whether, where and when brachytherapy will occur.[3]
Ask radiation oncology to define:
- target and dose for external-beam treatment;
- concurrent systemic agent, if any;
- brachytherapy technique, applicator, anaesthesia and imaging guidance;
- total treatment time and how interruptions are managed;
- bladder, bowel, marrow, kidney and ovarian exposure;
- prior radiation dose that must be imported; and
- management of vaginal stenosis, menopause, bowel or bladder effects and sexual health.
If external-beam treatment is in China and brachytherapy elsewhere, both centres should agree on sequence, dose summation, file format and acceptance before the first fraction. “Referral later” is not a safe handover.
Systemic treatment requires histology, biomarkers and a line-of-therapy record
Chemotherapy, immunotherapy, anti-angiogenic, PARP-inhibitor and hormone strategies are not interchangeable across gynaecologic cancers. The order depends on primary site, histology, stage, prior exposure, response, residual disease, molecular results, organ function and treatment availability.[1][2][3]
The written systemic plan should include regimen, dose basis, cycle interval, planned number of cycles, response assessment, dose-modification thresholds and supportive medicines. Record every prior agent with dates, dose reductions, best response and reason stopped. “Six rounds of chemotherapy” is not enough for recurrent-disease planning.
Biomarkers need a clinical question and specimen source. Examples include mismatch-repair or microsatellite status, POLE and p53 classification in endometrial cancer; BRCA and homologous-recombination information in tubo-ovarian cancer; PD-L1 or other treatment-specific markers where required; and hormone receptors in selected tumours. Separate tumour-only findings from confirmed germline results.
Genetics is treatment information and family information
NCI identifies BRCA1/2 and other genes in ovarian-cancer susceptibility and Lynch-syndrome mismatch-repair genes in endometrial and ovarian cancer risk.[7] A genetic pathway should specify whether testing is tumour, germline or both; who provided pre-test counselling; how a pathogenic, negative or uncertain result will change treatment; and what relatives may need to know.
Do not translate a variant of uncertain significance into “hereditary cancer confirmed.” Conversely, a negative tumour panel does not automatically exclude every inherited syndrome. Obtain the complete laboratory report, genes and methods, not a screenshot of a summary.
Protect fertility, hormones and sexual function before they are lost
NCI advises discussing fertility with the cancer and fertility teams before treatment that may impair it.[5] Options can include egg or embryo freezing, ovarian-tissue preservation in selected settings, ovarian transposition before pelvic radiation, and carefully selected fertility-sparing cancer surgery. These options take time and are not safe or appropriate for every tumour.
For cervical cancer, conisation or radical trachelectomy can preserve the uterus in some small early cancers, with strict pathological and nodal criteria.[6] For selected low-risk endometrial disease, conservative hormone-based management may sometimes be discussed by specialist teams, but it requires confirmed eligibility, repeated endometrial assessment and a plan for definitive treatment. Preserving one ovary and the uterus may be possible for selected early ovarian tumours depending on histology and stage; “ovarian cancer” alone is too broad to decide.
Ask separately about:
- ability to produce eggs;
- ability to carry a pregnancy;
- safety and timing of pregnancy after treatment;
- ovarian failure and menopausal symptoms;
- whether hormone replacement is appropriate for this tumour;
- vaginal, vulvar, bladder, bowel and pelvic-floor effects; and
- contraception during and after therapy.
Fertility preservation should not delay urgent cancer treatment without an explicit oncologic assessment of that delay.
Supportive care starts with the first treatment, not after options run out
Anaemia, pain, nausea, thrombosis, nutrition, bowel or urinary obstruction, neuropathy, lymphoedema, menopause, sexual dysfunction, anxiety and financial burden can undermine treatment even when tumour-directed therapy is correct. Assign each problem to a service and define escalation criteria.
Palliative care can be added alongside treatment for symptom control and decision support. It does not mean abandoning anticancer care. For recurrent disease, ask what outcome the next line is expected to improve and what finding would indicate that burden has exceeded benefit.
Build a handover that the home team can use
Before returning home, collect:
- final pathology and molecular reports with specimen identifiers;
- DICOM imaging and formal reports;
- operation note, residual-disease and complication record;
- radiotherapy plan, dose, fractions and DICOM-RT files when relevant;
- systemic-treatment administration record and toxicity history;
- current medicines, thrombosis plan and allergies;
- fertility, menopause, sexual-health and rehabilitation plan;
- surveillance schedule tied to cancer type and treatment; and
- named contacts for pathology, surgery, radiation and medical oncology.
Surveillance is not one universal schedule and should not rely on tumour markers alone. It may include symptom review, examination, cancer-specific imaging or laboratory assessment. Clarify which clinician acts on an abnormal result and who manages urgent complications when the patient is no longer in China.
Medical disclaimer: This article provides general education and cannot establish a cancer diagnosis, stage, operability, treatment sequence or fertility-sparing eligibility. Decisions require site-specific specialist review of pathology, imaging and the patient's condition. Acute bleeding, fever or other severe symptoms need urgent local care.
FAQ
Which specialist should lead a gynaecologic-cancer case?
A gynaecologic oncologist commonly coordinates the core plan, but leadership may shift by phase—for example, to radiation oncology during chemoradiation or medical oncology during systemic therapy. The written plan should name who owns the next step and complications.
Is a pathology report from my home country enough?
It may be enough to start triage, but treatment can require review of slides or blocks, confirmation of primary site and histology, and additional immunohistochemical or molecular tests. Send the report and arrange access to the original material before travel.
Does every ovarian cancer patient need surgery first?
No. Some patients have primary cytoreductive surgery, while others have tissue diagnosis and chemotherapy before interval surgery because of disease distribution, medical fitness or the likelihood of complete cytoreduction.[1] The MDT should document the reason.
Can fertility be preserved after a gynaecologic-cancer diagnosis?
Sometimes, in carefully selected early cancers or through fertility-preservation procedures before treatment.[5][6] Eligibility depends on exact histology, stage, biomarkers, urgency and reproductive goals; no option guarantees a future pregnancy.
What proves that a multidisciplinary review actually occurred?
A useful record names participants or specialties, diagnosis, stage, reviewed evidence, treatment intent, agreed sequence, alternatives, unresolved questions, contingency branches and the clinician responsible for the next action. A generic coordinator message is not equivalent.
Sources
- US National Cancer Institute — Ovarian Epithelial, Fallopian Tube and Primary Peritoneal Cancer Treatment (PDQ)
- US National Cancer Institute — Endometrial Cancer Treatment (PDQ)
- US National Cancer Institute — Cervical Cancer Treatment (PDQ)
- US National Cancer Institute — Vulvar Cancer Treatment (PDQ)
- US National Cancer Institute — Female Fertility and Cancer Treatment
- US National Cancer Institute — Cervical Cancer Treatment by Stage and Fertility-Sparing Options
- US National Cancer Institute — Genetics of Breast and Gynecologic Cancers (PDQ)
- National Health Commission of China — National Cancer and Blood-Disease Diagnosis and Treatment Guidelines (2022)
Image Review
- Decision: Replaced with a topic-specific ImageGen hero and visually reviewed for medical relevance, obvious generation artifacts and bilingual reuse.
- Editorial note: The original shows one clinician presenting an abstract service pathway to a patient and companion. It contains no pelvic imaging, pathology, cancer anatomy or multidisciplinary participation and therefore cannot support a gynaecologic-oncology planning article.